english.prescrire.org > Spotlight > 100 most recent > Insulin icodec (Awiqli°) in type 1 or type 2 diabetes

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Insulin icodec (Awiqli°) in type 1 or type 2 diabetes

 Marketing Authorisations  Insulin icodec is a long-acting analogue of human insulin, designed for once-weekly subcutaneous injection. It differs from human insulin by a few amino acids and the addition of a fatty acid to one of the insulin chains. It has been authorised in the European Union for use in adults with type 1 or type 2 diabetes. Does insulin icodec represent a therapeutic advance over the long-acting insulins available for once-daily use? 
Full article available for download by subscribers

 ©Prescrire 1 October 2025

Source: "Insulin icodec (Awiqli°) in type 1 or type 2 diabetes" Prescrire Int 2025; 34 (274): 229-231. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information